Recardio

Regenerative Cardiac Medicine of Tomorrow

  • Company
    • Profile
    • Management Board
    • Boards
    • Awards
  • Pipeline
    • Background
    • Rationale
    • Therapy
  • Clinical Studies
    • Phase 1
    • Phase 2B AMI
    • Phase 2B CHF
  • News
  • Apps
    • App Privacy Policy

May 28 2018

Recardio initiates patient recruitment for Phase 2 Study Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction

San Francisco, May 28, 2018 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that it is starting recruiting patients for its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Recruitment for this randomized, double-blind, placebo-controlled trial will begin in one of the 29 participating trial centers in the European Union and be expanded rapidly to also include 5 centers in the United States.  

Read More

Written by Recardio · Categorized: Uncategorized

Jan 31 2018

Recardio receives FDA approval for Phase 2 Study

San Francisco, January 31st, 2018 – Recardio Inc. today announced that it has received the FDA approval for its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction.

Read More

Written by Recardio · Categorized: Uncategorized

Oct 17 2017

Recardio presented at BIO Investor Forum 2017 in San Francisco

San Francisco, Oct. 17, 2017 – Recardio presented today its clinical regenerative therapy program for cardiovascular diseases at the international BIO Investor Forum 2017 in San Francisco.

Read More

Written by Recardio · Categorized: Uncategorized

Oct 12 2017

Recardio completes Phase 1 Study

San Francisco, October 12th, 2017 – Recardio Inc. successfully completes Phase 1 study for Dutogliptin.

Read More

Written by Recardio · Categorized: Uncategorized

Aug 28 2017

Umbrella Patent for the treatment of cardiovascular diseases in the EU

San Francisco, Aug. 28th, 2017 – RECARDIO, announced that the European Patent Office (EPA) has issued the notice of allowance for its innovative use patent for the treatment of ischemic diseases.

Read More

Written by Recardio · Categorized: Uncategorized

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
  • Contact us
  • Imprint
  • Data Privacy

© Recardio inc. 2019 · All Rights Reserved

Copyright © 2019 · Genesis Framework · WordPress · Log in